Sebacia
2905 Premiere Parkway, Suite 150
Duluth
Georgia
30097
United States
Tel: 888-935-4411
Website: http://www.sebacia.com/
Email: info@sebacia.com
15 articles about Sebacia
-
Sebacia Announces Leadership Update and Acquisition of Silver Photoparticle Technology Assets from Sienna Biopharmaceuticals
1/9/2020
Sebacia, Inc., a privately held commercial stage dermatology and aesthetics company, today provided a business update, first announcing an update to its leadership team.
-
Sebacia Reports New Long-Term Real-World Results Demonstrating 92% Average Improvement in Acne at 24 Months
10/25/2019
Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced new positive real-world results from its two registry studies evaluating the Company's proprietary Sebacia Microparticles in Europe and the U.S. The results were presented at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting in two oral presentations.
-
Sebacia Announces Oral Presentations Reporting 24-Month EU Real-World Data and 3-Month U.S. Real-World Data of Sebacia Microparticles at ASDS Annual Meeting 2019
10/24/2019
Oral presentations by Jill Waibel, MD and Ashish Bhatia, MD
-
Sebacia to Present 12-Month Durability Data and New in Vivo Imaging Data for Sebacia Microparticles at ASLMS Annual Meeting 2019
3/26/2019
Oral presentations by Jill Waibel, MD and Merete Hædersdal, MD, PhD, DMSc
-
Sebacia EU Real-World Results Demonstrate 85% Durable Improvement in Acne at 12 Months
3/1/2019
Presented by leading dermatologists Jill Waibel, MD and Arielle Kauvar, MD at AAD Annual Meeting 2019
-
Sebacia to Present New 12-Month Durability Results from EU Real-World Acne Study at AAD Annual Meeting 2019
2/27/2019
Oral presentations by leading dermatologists Jill Waibel, MD and Arielle Kauvar, MD
-
Sebacia EU Real-World Results Demonstrate an Average 79% Improvement in Acne at 6 Months
10/11/2018
Oral presentation today at ASDS Annual Meeting by leading dermatologist Ashish Bhatia, MD
-
Sebacia Highlights Oral Presentation of EU Real-World Pre-Conditioning Study Results at ASDS Annual Meeting 2018
10/8/2018
Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that results from its real-world pre-conditioning study in Europe evaluating Sebacia Microparticles for treatment of facial acne has been accepted for an oral presentation
-
U.S. FDA Clears Sebacia Microparticles for the Treatment of Mild to Moderate Inflammatory Acne
9/17/2018
U.S. Commercial Launch of Cash-Pay Product Anticipated in Mid-2019
-
Sebacia Announces Presentation of Data Demonstrating Sebacia Microparticles as an Effective Contrast Enhancing Agent for Potential Use in Evaluating Dermatologic Conditions
4/9/2018
Sebacia, Inc. will present data showing Sebacia Microparticles could help improve dermatologic imaging by acting as a contrast enhancing agent.
-
Sebacia Announces $36 Million Equity And Debt Financing To Advance Breakthrough In-Office Procedure For Acne
7/25/2017
-
Sebacia Announces Completion Of Enrollment In Pivotal U.S. Clinical Trial For Severe Acne
10/7/2015
-
Sebacia Announces Series C Financing To Advance Innovative Dermatology Treatment For Acne
6/25/2015
-
Sebacia Announces New Vice President, Engineering And Program Management
6/25/2015
-
Sebacia Release: Study Points Way To New Treatment Procedure For Acne
3/20/2015